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Abstract
Background: Cervical cancer is associated with infection by certain subtypes of human papillomavirus (HPV). The
L1 protein comprising HPV vaccine formulations elicits high-titre neutralizing antibodies and confers protection
against specific HPV subtypes. HPV L2 protein is an attractive candidate for cross-protective vaccines. HPV-33 and
HPV-58 are very prevalent among Chinese women.
Methods: To study the gene intratypic variations and polymorphisms of HPV-33 and HPV-58 L1/L2 in Sichuan
China, HPV-33 and HPV-58 L1 and L2 genes were sequenced and compared with other genes submitted to
GenBank. Phylogenetic trees were constructed by maximum-likelihood and the Kimura 2-parameters methods
(MEGA 6). The secondary structure was analyzed by PSIPred software, and HPV-33 and HPV-58 L1 homology
models were created by SWISS-MODEL software. The selection pressures acting on the L1/L2 genes were
estimated by PAML 4.8.
Results: Among 124 HPV-33 L1 sequences 20 single nucleotide mutations were observed included 8/20 non-
synonymous and 12/20 synonymous mutations. The 101 HPV-33 L2 sequences included 12 single nucleotide
mutations comprising 7/12 non-synonymous and 5/12 synonymous mutations. The 223 HPV-58 L1 sequences
included 32 single nucleotide mutations comprising 9/32 non-synonymous and 23/32 synonymous mutations.
The 201 HPV-58 L2 sequences comprised 26 single nucleotide mutations including 9/26 non-synonymous and
17/26 synonymous mutations. Selective pressure analysis showed that most of the common non-synonymous
mutations showed a positive selection. HPV-33 and HPV-58 L2 were more stable than HPV-33 and HPV-58 L1.
Conclusions: HPV-33 and HPV-58 L2 were better candidates as clinical diagnostic targets compared with HPV-
33 and HPV-58 L1. Clinical diagnostic probes and second-generation polyvalent vaccines should be designed
on the basis of the unique sequence of HPV-33 and 58 L1/L2 variations in Sichuan, to improve the accuracy
of clinical detection and the protective efficiency of vaccines.
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Background
Human papillomavirus (HPV) infection plays a critical
role in the development of cervical cancer [1]. The risk
of developing cervical cancer in HPV-infected patients is
50-fold higher than in uninfected women [1, 2]. Ap-
proximately 500000 new cases of cervical cancer are di-
agnosed every year, with 250000 deaths, more than 85 %
of all patients belong to low-income countries [3, 4].
Genital HPV subtypes are typically divided into two
groups according to their presumed oncogenic potential.
High-risk oncogenic HPV subtypes −16, −18, −58, −33,
−52 and −45 are more common in Asia than elsewhere
[5]. HPV-33 and HPV-58 are prevalent among Chinese
women, only after HPV-16 [6–8]. HPV-33 and HPV-58
account for approximately 5 and 2 % of cervical cancer
cases world-wide [9, 10]. Nevertheless, the carcinoma in
situ and cervical cancer cases caused by HPV-58 and
HPV-33 outnumber HPV-18, ranking second and third
in China, respectively [6, 11]. Compared with the high-
risk HPV-18, vaccine design in China is focused pre-
dominantly on high-risk subtypes HPV-58, and HPV-33.
The HPV genome is packaged within the major capsid
late protein L1 and the minor capsid proteins L2 [12, 13].
Five L1 proteins form a pentamer, and 72 pentamers con-
stitute the virus capsid. The L1 and L2 proteins self-
assemble into virus-like particles (VLPs) that induce high
levels of neutralizing antibodies and are highly protective
[14, 15]. The L1-VLPs are the components used in the de-
sign of specific prophylactic vaccines. Vaccine targeting L1
only prevents infection by specific HPV subtypes because
of the lack of cross-protective epitopes in different HPV
subtypes. HPV L2 protein also induces neutralizing
antibodies, the N-terminal of L2 protein contains cross-
protective epitopes and represents the target of neutraliz-
ing antibodies [14]. Therefore, targeting L2 may be an
attractive approach for a candidate vaccine.
Vaccines against HPV-16, HPV-18, HPV-6 and HPV-
11 L1 are available [15]. The two HPV vaccines Gardasil
and Cervarix target only two high-risk HPV subtypes.
Prevention of more than 90 % of HPV infections re-
quires targeting at least 5 additional high-risk HPV sub-
types HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58
[16]. Vaccines targeting L2 and other subtypes of L1 are
currently under investigation [14].
The data supporting HPV-58 L2 and HPV-33 L1/L2 in
China are limited. The molecular variants of HPV-33 L1/
L2 worldwide are not widely reported. Ethno-geographical
variations are observed in distribution of HPV subtypes.
Among different subtypes of HPV, there are subtypes and
variants that can acquire biological advantages through
fixed mutations in their genomes, and even small varia-
tions could result in small adaptive improvements that
could alter the composition of an HPV-infected popula-
tion [17]. Altered amino acid composition affects the host
immune response, and in such cases, intra-type protection
may be less effective [18]. Ideally, the diagnosis and treat-
ment of vaccine constructs needs to be developed locally.
This study investigated the HPV-33 and HPV-58 L1/
L2 gene polymorphism and intratypic variations in
Sichuan, China. This study can provide essential data for
future research on viral prevention and therapeutics.
Above all, our study provides critical data facilitating the
development of diagnostic probes and design of vaccines
based on HPV-33 and HPV-58 L1/L2.
Methods
Study population and specimen collection
Cervical specimens were collected from Sichuan Repro-
ductive Health Research Center Affiliated Hospital, The
Angel Women’s and Children’s Hospital, The Chengdu
Western Hospital Maternity Unit, and The Peoples’
Hospital of Pengzhou, and other institutions. Between
January 1, 2009, and December 31, 2014, women pre-
senting for cervical screening underwent histology and
cytology evaluations for cervical disease. Women over
14 years of age and with visible cervical lesions and/or
HPV-related diseases (e.g., cervicitis, cervical intrae-
pithelial neoplasia) were eligible for inclusion. Cervical
specimens were collected from participants and placed
in a preservative buffer and stored at −20 °C.
Genomic DNA extraction
HPV-DNA was extracted and examined using a Human
Papillomavirus Genotyping Kit (Yaneng Bio, Shenzhen,
China) according to the manufacturer’s instructions.
This kit enabled the classification of 23 HPV subtypes
(18 types of high-risk HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 73, 83, MM4 and five types of
low-risk HPV genotypes 6, 11, 42, 43, and 44). In total,
478 HPV-58 and 273 HPV-33 positive samples were
collected.
PCR amplification and sequencing
The entire L1/L2 genes of HPV-33 and HPV-58 were
amplified using primer pairs. The primers were designed
according to the GeneBank reference sequences for
HPV-33 (GenBank: M12732.1) and HPV-58 (GenBank:
D90400). The primer sequences were listed in Table 1.
Each 50 μL PCR reaction contained 5 μL of extracted
DNA (10–100 ng), 200 μmoL MgCl2 and dNTPs, 2 U of
Pfu DNA polymerase (Sangon Biotech, Shanghai, China),
and 0.25 μmoL of each primer. The PCR conditions
were 95 °C for 10 min; 35 cycles of 50 s each at 94 °C,
54 °C (difference for each gene) for 60 s, 72 °C for 60 s,
and a final step of 72 °C for 7 min. The PCR amplifica-
tion products were visualized on 2 % agarose gels
stained with GeneGreen nucleic acid dye under the ultra
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violet light WFH-202. Target products were sequenced
by Sangon Biotech.
Variant identification and analysis
The sequences and variations were analyzed by NCBI
Blast, and DNAMAN version 5.2.2. The nucleotide posi-
tions were numbered according to the GeneBank refer-
ence sequences of HPV-33 (GenBank: M12732.1) and
HPV-58 (GenBank: D90400). All the data were con-
firmed by repeating PCR amplification and sequence
analysis at least twice.
Phylogenetic trees analysis
Then, phylogenetic trees of respective HPV-33 L1/L2
and HPV-58 L1/L2 variation patterns were con-
structed with the maximum-likelihood trees using
MEGA (Molecular Evolutionary Genetics Analysis
Version) 6 software and Kimura’s two-parameter model.
The tree topologies were evaluated using bootstrap
resampled 1,000 times [19].
Analysis of the selection pressures and secondary
structure
To estimate the positive selections at particular sites of the
HPV-33 and HPV-58 L1/L2 gene sequences, the codeml
program in the PAML (Phylogenetic Analyses by Maximun
Likelihood) version 4.8 package was used to perform the
likelihood ratio tests (LRTs) to infer non-synonymous and
synonymous nucleotide divergence for coding regions by
the method of Nei and Gojobor [20–23]. The secondary
structure of the reference sequences were analyzed by
PSIPred servers at (http://bioinf.cs.ucl.ac.uk/psipred).
PSIPred is a simple and accurate secondary structure pre-
diction method, incorporating two feed-forward neural net-
works, which enable the analysis of output obtained from
PSI-BLAST (Position Specific Iterated-BLAST). A very
stringent cross validation of the method indicated that
PSIPred 3.2 attained an average Q3 score of 81.6 % [24].
Homology models analysis
HPV33 and HPV58 L1 homology models were created by
SWISS-MODEL (http://swissmodel.expasy.org/) based on
the crystal structure of the HPV16 L1 pentamer [25, 26],
and then visualized using Swiss-PDP viewer V4.0
software.
Results
Of all the HPV-58 and HPV-33 samples, only 223
sequences of HPV-58 L1 gene, 201 sequences of the
HPV-58 L2 gene, 124 sequences of the HPV-33 L1 gene,
and 101 sequences of the HPV-33 L2 gene were obtained
owing to the small number of copies of infected HPV in
some women and limited amplicons obtained for
sequencing, and there maybe a potential sampling bias
against integrated HPV genomes resulting in lost capsid
genes.
Gene polymorphism of HPV-33 L1
Compared with the HPV-33 reference sequence (Gen-
Bank: M12732.1), the nucleotide variation rate of HPV-
33 L1 was 68.55 % (85/124) in the 124 HPV-33 L1
sequences studied. We identified 20 single nucleotide
changes among the 124 sequences studied. Specifically,
12/20 (60.00 %) were synonymous and 8/20 (40.00 %)
Table 1 Primers used for the molecular characterization of HPV-33 and HPV-58 L1 and L2
Gene Primer name Sequence 5′ to 3′ Primer position Product size (bp) Annealing Temperature
33 L1 HPV33 L1 1 F ATTTGTTCCTATTTCGCCT 5468 921 54 °C
HPV33 L1 1R CAGCCCTATTAAAAAAGTGTC 6388
HPV33 L1 2 F CAGTACATGCAAATATCCAGATTA 6271 913 54 °C
HPV33 L1 2R ACATACACAAAAAACAAACAACA 7183
33 L2 HPV33 L2 1 F GCACATGGTGGTGTTTTAAC 4116 935 54 °C
HPV33 L2 1R AGTCAGGATCAGGAGCAGGT 5050
HPV33 L2 2 F AATGTAACATCAAGCACGCC 4834 994 55 °C
HPV33 L2 2R TAAACGGACCCTAAAAACCC 5827
58 L1 HPV58 L1 1 F TCCATTTATTCCTATATCTCCACTA 5515 876 56 °C
HPV58 L1 1R GAAAAAAGAACAAACTATCCCCA 6390
HPV58 L1 2 F ATGGTAGATACAGGGTTTGGAT 6240 1044 55 °C
HPV58 L1 2R AAACAGGAAACTGACAAAGACA 7283
58 L2 HPV58 L2 1 F GTATACTGGTTATGCACATGGT 4125 847 54 °C
HPV58 L2 1R AAAAAAGCAGGGTCAACAAC 4971
HPV58 L2 2 F AATGGATACCTTTGTTATTTCTAC 4834 992 54 °C
HPV58 L2 2R TACTTTTTTATTGTTATTGGGACT 5825
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were non-synonymous mutations. Only 1 non-
synonymous mutation was observed in sequence encod-
ing the helix. The detected mutations are summarized in
Table 2. The maximum-likelihood phylogenetic tree can
be seen in Fig. 1a. The secondary structure predicting
result of the HPV-33 L1 was showed in Additional file 1:
Figure S1 (A).
Gene polymorphism of HPV-33 L2
Compared with the HPV-33 reference sequence (Gen-
Bank: M12732.1), the nucleotide variation rate of HPV-
33 L2 was 100.0 % (101/101) in the 101 HPV-33 L2
sequences studied. We identified 12 single nucleotide
changes among the 101 L2 sequences studied. Specific-
ally, 5/12 (41.7 %) were synonymous mutations and 7/12
(58.3 %) were non-synonymous mutations. The detected
mutations are summarized in Table 3. The maximum-
likelihood phylogenetic tree is represented in Fig. 1b.
The secondary structure predicting result of the HPV-
33 L2 was showed in Additional file 1: Figure S1 (B).
HPV-58 L1 gene polymorphism
Compared with the HPV-58 reference sequence (Gen-
Bank: D90400), the nucleotide variation rate of HPV-58
L1 was 96.86 % (216/223) in the 223 HPV-58 L1
sequences studied. We identified 32 single nucleotide
changes among the 223 sequences studied.
Specifically, 23/32 (71.88 %) were synonymous mutations
and 9/32 (28.12 %) were non-synonymous mutations. 3
non-synonymous mutations were observed in sequences
encoding the helix, 1 non-synonymous mutation was ob-
served in sequence encoding the sheet. The detected muta-
tions are summarized in Table 4. The maximum-likelihood
phylogenetic tree is shown in Fig. 2c. The secondary struc-
ture predicting result of the HPV-58 L1 was showed in
Additional file 2: Figure S2 (C).
HPV-58 L2 gene polymorphism
Compared with the HPV-58 reference sequence (Gen-
Bank: D90400), the nucleotide variation rate of HPV-58
L2 was 68.55 % (168/201) in the 124 HPV-58 L2 se-
quences studied. We identified 26 single nucleotide
Table 2 Nucleotide sequence mutation at L1 of 13 HPV-33 isolates
Sequence pattern HPV33 L1 Nucleotide sequence n Sub-lineages
5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7
7 9 9 9 3 3 3 4 4 4 5 5 6 6 6 6 7 9 0 0
6 6 9 9 8 9 9 6 7 8 2 4 1 6 7 9 4 5 4 6
0 0 0 7 5 0 6 3 8 7 0 4 3 4 3 4 8 1 4 3
M12732 C T G A T C G T T A G A T A A A A A C G
KU550663 - - - - - - - - - - - - - - - - - - - - 39 A1
KU550664 - C - - - - - - - - - - - - - - - - - - 4 A1
KU550665 - - - - - - - - - - - - - - - - - C - - 1 A1
KU550666 - - - - - - - - - - - - - - - G - - - - 1 A1
KU550667 - - - - - - - - - - - - - - - - - - A - 2 A1
KU550668 - - - - - - - - - - - - - - - - - - - A 54 A1
KU550669 - - - - - - - - - - - - C - - - - - - A 1 A1
KU550670 - - - - - - - - - - A - - - - - - - - A 2 A1
KU550671 - - - - G - - - - - - - - - - - - - - A 1 A1
KU550672 - - - - - - - - - C - - - - - - - - - - 1 A1
KU550673 - - - G - A A - - - - G - G - - - - - - 4 A1
KU550674 - - - - - A A C - - - G - G - - - - - - 1 A1
KU550675 A - A - - A - - C - - - C G G - C - - - 13 A2
G K T G E K P
T 1 1 2 2 3 4 4
aa mutation 5 - 3 3 - 6 6 - - - - - - - - - 8 5 8 - 124
6 3 5 6 8 5 3 4
N S R K E D T H
second struture - - - - - - - - - - H - - H H - H - - -
Note: M12732 was used as reference. The nucleotides conserved with respect to the reference sequence are marked with a dash(-), whereas a variation position
was indicated by a letter. Predicted amino acid changes were also shown. The “S” in the last row of the table means Sheet, the “H” means Helix
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Fig. 1 Maximum-likelihood trees of HPV-33 variants. Note: Phylogenetic trees based on the Maximum-likelihood method of representing the relationships
between variants of HPV-33, (a) Tree based on gene L1, (b) Tree based on gene L2. Sub-lineage classification based on full genomes from
a reported research [27], and one or two representative sequences were chosen from each branch of the tree, respectively (AS099-A1/
HQ537697, INCC0137-A2/HQ537699, QV34060-A2/HQ537698, QV23819-B/HQ537705, QV34189-B/HQ537707). Numbers above the branches
indicate the bootstrap values that are greater than 70 %
Table 3 Nucleotide sequence mutation at L2 of 8 HPV-33 isolates
Sequence pattern HPV33 L2 Nucleotide sequence n Sub-lineages
4 4 4 4 5 5 5 5 5 5 5 5
4 6 8 9 0 0 2 2 2 3 3 4
3 7 0 0 2 5 2 5 8 1 2 5
8 1 9 5 6 1 0 7 7 4 4 7
M12732 G T C C A T C G G G A C
KU518344 - - - - - - T - - - - - 73 A1
KU518345 - - - - - - T - - A - - 3 A1
KU518346 - - - - - - T - - - - T 1 A1
KU518347 - - - - G T - - - - - 1 A1
KU518348 - - - - - A T - - - - - 8 A1
KU518349 A - - - - - T - - - - - 6 A1
KU518350 A - A T - - T - - - - - 3 A1
KU518351 A C - T - - T C A - C - 6 A2
I F D D D N
D 2 2 3 3 3 3
aa mutation 7 - - - 7 8 - 5 6 6 7 - 101
7 3 1 0 0 9 2
N V Y H N N T
second struture - S - S - - - - - - - -
Note: M12732 was used as reference. The nucleotides conserved with respect to the reference sequence are marked with a dash(-), whereas a variation position
was indicated by a letter. Predicted amino acid changes were also shown. The “S” in the last row of the table means Sheet, the “H” means Helix
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Table 4 Nucleotide sequence mutation at L1 of 37 HPV-58 isolates
Sequence
pattern
HPV58 L1 Nucleotide sequence n Sub-
lineages
5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
7 7 8 8 8 8 8 8 8 9 0 4 4 4 4 4 4 4 5 5 5 5 5 5 6 6 6 7 7 8 8 8 8 9
4 9 0 0 0 2 2 3 7 8 1 0 1 3 3 5 7 8 0 0 1 2 3 6 4 8 9 9 9 2 2 6 8 9
7 8 1 7 9 2 8 4 3 4 4 4 6 4 7 8 0 5 0 3 7 1 9 0 1 8 5 7 8 7 9 0 1 9
D90400 T C A C A A A C T G A G A T A G T T C A T A A A G C A G A C A A A A
KU550602 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 7 A1
KU550603 - - - A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 13 A1
KU550604 - - - - - - - - - - - - - - G - - - - - - - - - - - - - - - - - - - 4 A1
KU550605 - - - - - - - - - - - - - - - - - - - G - - - - - - - - - - - - - - 2 A1
KU550606 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G - - 31 A1
KU550607 - - - - - - - - - - - - - - - - - - - - - - - - - - C - - - - G - - 1 A1
KU550608 - - - - - - - - - - - - - - - - - - - - - - - - - - C A - - - - - - 1 A1
KU550609 - - - - - - G - - - - - - - - - - - - - - - - - - - - - - - - - - - 1 A1
KU550610 - - - - - - - - - - - - - - - A - - - - - - - - - - - - - - - - - - 4 A1
KU550611 - - - - - - - - - - - A - - - - - - - - - - - - - - - - - - - - - - 5 A1
KU550612 - - - - - - - - - - - - - - - - - - - - - - - G - - - - - - - - - - 4 A1
KU550613 - - - - - - - - - - C - - - - - - - - - - - - G - A - - - - - - - - 1 A1
KU550614 C - - - - - - - - - C - - - - - - - - - - - - G - A - - - - - - - - 2 A1
KU550615 - - - - - - G - - - C - - - - - - - - - A - - - - A - - - - - - - - 1 A1
KU550616 - T - - C - - A - - C - - - - - - - - - A - - - - A - - - - - - - - 3 A1
KU550617 - - - - - - - - - - - A - - - - - - - - - - - G - A - - - - - - - - 2 A1
KU550618 - - - - - - - - - - - - - - - A - - - - - - - G - A - - - - - - - - 3 A1
KU550619 - - - - - - - - - - - - - - - - - - - - - - - G - A - - - A - - - - 2 A1
KU550620 - - - - - G - - - - - - - - - - - - - - - - - G - A - - - - - - - - 1 A1
KU550621 - - - - - - - - - - - - - - - - - - - - - - - G - A - - - - - - - - 36 A1
KU550622 - - - - - - - - - - - - - - - - C - - - - - - G - A - - - - - - - - 6 A1
KU550623 - - - - - - - - - A - - - - - - - - - - - - - G - A - - - - - - - - 3 A1
KU550624 - - - - - - - - - - - - - - - - - - - - - - - G - A - - - - C - - - 2 A1
KU550625 - - - - - - - - - - - - G C - - - - - - - - G - A - - - - - - - - - 1 A2
KU550626 - - - - - - - - - - C - G C - - - C - - - - G - A - - - - - - - - - 6 A2
KU550627 - - - - - - - - - - - - G C - - - C - - - - G - A - - - - - - - - - 1 A2
KU550628 - - - - - - - - - - C - G C - - - - - - - - G G A - - - - - - - - - 2 A2
KU550629 - - - - - - - - - - C - G C - A - - - - - - G - A - - - - - - - - - 4 A2
KU550630 - - - - - - G - - - C - G C - - - - - - - G G - A - - - - - - - - - 4 A2
KU550631 - - - - - - - - - - C - G C - - - - - G - - G - A - - - - - - - - - 3 A2
KU550632 - - - - - - - - G - C - G C - - - - - G - - G - A - - - - - - - - - 2 A2
KU550633 - - G - - - - - - - C - G C - - - - - - - - G - A - - - - - - - - - 5 A2
KU550634 - - - - - - - - - - C - G C - - - - - - - - G - A - - - - - - - - - 28 A2
KU550635 - - - - - - - - - - C - G C - - - - - - - - G - A - - - - - - - - C 9 A2
KU550636 - - - - - G - - - - - - - - - - - - - - - - G - - - - - - A - - - - 5 A3
KU550637 C - - - - - - - - - C - - - - - - - - - - - G - - - - - - A - - - - 8 A3
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changes among the 201 L2 sequences studied. Specific-
ally, 17/26 (65.38 %) were synonymous and 9/26
(34.62 %) were non-synonymous mutations. 3 non-
synonymous mutations were observed in sequences
encoding the sheet. The detected mutations are summa-
rized in Table 5. The maximum-likelihood phylogenetic
tree is displayed in Fig. 2d. The secondary structure pre-
dicting result of the HPV-58 L2 was showed in
Additional file 2: Figure S2 (D).
Selective pressure analysis
The variable dN/dS rate ratios were tested among the
various lineages using the PAML4.8 [10]. HPV-33 L1-
positive selection was seen with T56N, G133S, K135R,
T226K, G268E and E385D. HPV-33 L2-positive selection
was seen in D77N, D350H, D360N and N372T. The
HPV-58 L1-positive selection included L150F, F318Y,
I325M, T375N and E377D. The HPV-58 L2-positive
lineages included N231T, A416T and M446L. Results of
the selective pressure analysis of HPV-58 and HPV-33
L1 and L2 genes (P-value, 0.1) are summarized in
Tables 6, 7, 8 and 9.
Homology models analysis
HPV-16, 33, and 58 are known to be closely related
and belong to the α-9 species. The whole protein se-
quences of HPV-16, 33, and 58 L1 were aligned
(Additional file 3: Figure S3) and the BC-loop, DE-loop,
EF-loop, FG-loop, and HI-loop of HPV-33 and HPV-58 L1
were predicted in the present study (Fig. 3). G4438A
(T56N) of HPV-33 L1 and A5809C (N82T) of HPV-
58 L1 were found in the BC-loop; G5990A (G133S) and
G5997A (K135R) of HPV-33 were found in the DE-loop;
C6390A (T266K) and G6396A (G268E) of HPV-33 L1
were found in the FG-loop; and C6688A (T375N) and
Table 4 Nucleotide sequence mutation at L1 of 37 HPV-58 isolates (Continued)
KU550638 C - - - - - - - - - C - - - - - - - T - - - G - - - - - G A - - G - 10 A3
L F I T E I N K
N 1 3 3 3 3 4 4 4
aa mutation - - - - 8 - - - - - 5 - - - - - - - - - 1 - 2 - - 7 7 - 1 - 2 - - 7 223
2 0 8 5 5 7 2 2 9
T F Y M N D V T Q
second
structure
S S S - - - S - S - - H H - - - - - - - H S S - S - - H H - - - - -
Note: D90400 was used as reference. The nucleotides conserved with respect to the reference sequence are marked with a dash(-), whereas a variation position
was indicated by a letter. Predicted amino acid changes were also shown. The “S” in the last row of the table means Sheet, the “H” means Helix
Fig. 2 Maximum-likelihood trees of HPV-58 variants. Note: Phylogenetic trees based on the Maximum-likelihood method of representing
the relationships between variants of HPV-58, (c) Tree based on gene L1, (D) Tree based on gene L2. Sub-lineage classification based on
full genomes from a roported research [27], and a representative sequence were chosen from the tree, respectively (LZCC86-A1/EU918765, TJ18-A2/
GQ472850, QV00961-A3/HQ537758). Numbers above the branches indicate the bootstrap values that are greater than 70 %
Chen et al. Virology Journal  (2016) 13:167 Page 7 of 12
Table 5 Nucleotide sequence mutation at L2 of 24 HPV-58 isolates
Sequence
pattern
HPV58 L2 Nucleotide sequence n Sub-
lineages
4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
4 4 5 5 5 6 6 6 9 9 0 0 0 1 1 2 2 3 3 4 4 4 4 5 5
5 7 4 5 7 0 2 2 3 4 0 0 1 1 4 0 6 2 9 3 6 8 8 4 7
2 0 9 8 0 9 1 7 5 5 0 0 4 9 3 6 6 6 5 7 7 2 9 0 9
D90400 G G T A G A A T A A G G A A T A G A G A A A G A A
KU550639 - - - - - - - - - - - - - - - - - - - - - - - - - 33 A1
KU550640 - - - - - - - C - - - - - - - G - - - - - - - - - 4 A1
KU550641 - - - - - - - - - - - - - - - G - - - - - - - - - 18 A1
KU550642 - - - - - - - C - - - - - - - - - - C - - - A - - 5 A1
KU550643 - - - - - - - C - - - - - - - - - T C - - - A - - 1 A1
KU550644 - - - - - - C C - - - - - - - - - T C - - - A - - 1 A1
KU550645 - - - - - - C C - - - - - - - - - - C - - - A - - 36 A1
KU550646 - A - - - - C C - - - - - - - - - - C - - - A - - 6 A1
KU550647 - - - - - - C C - - - C - - - - - - C - - - A - - 1 A1
KU550648 A - - - - - C C - - - - - - - - - - C - - - A - - 4 A1
KU550649 - - - G - - C C - - - - - - - - - - C - - - A - - 1 A1
KU550650 - - G G - - C C - - - - - - - - - - C - - - A - - 4 A1
KU550651 - - - - - - - C - G - - G G G - A - C - C - A - - 10 A2
KU550652 - - - - - - C C - G - - G G G - A - C - C - A - - 2 A2
KU550653 - - - - - - C C - G - - G G G - A - C - - - A C - 1 A2
KU550654 - - - - - G - C - G - - G G G - A - C - - - A C - 2 A2
KU550655 - - - - - - - C - G - - G G G - A C C - - - A C - 8 A2
KU550656 - - - - - - - C - G - - G G G - A - C - - T A C - 7 A2
KU550657 - - - - - - - C - G - - G G G - A - C - - - A C - 25 A2
KU550658 - - - - - - - C - G - - G G G - A - C G - - A C - 6 A2
KU550659 - - - - - - - C - G T - G G G - A - C G - - A C - 1 A2
KU550660 - - - - A G - C - - - - - - - - - - C - - - A - - 1 A3
KU550661 - - - - - - - - C - - - - - - - A - C - - - A - C 2 A3
KU550662 - - - - A G - C C - - - - - - - A - C - - - A - C 22 A3
N D D A T M
G S 2 2 2 4 4 4
aa mutation 7 7 - - - - - - 3 - 5 5 - - - - - - - - - - 1 3 4 201
0 6 1 3 3 6 3 6
E N T Y H T P L
second structure - - - - - - - - - S S S - S S - - - S - - - S - -
Note: D90400 was used as reference. The nucleotides conserved with respect to the reference sequence are marked with a dash(-), whereas a variation position
was indicated by a letter. Predicted amino acid changes were also shown. The “S” in the last row of the table means Sheet, the “H” means Helix
Table 6 Site-specific tests for positive selection on HPV-33 L1
Models InL Estimates of parameters 2Δl Positively selected sites
M7 −2415.234 p = 0.005 q = 0.048 NA
M8 −2395.143 p0 = 0.982 p = 0.114 q =6.861
(p1 = 0.018) ω = 16.384
40.183 p < 0.01 56 T**, 133G**, 135 K*, 266 T**, 268G**, 385E*
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A6695C (E377D) of HPV-58 L1 were found in the HI-
loop.
Discussion
In our previous study of 10682 patients, 3370 (31.5 %)
were positive for HPV infection. High-risk subtypes were
as follows: HPV16 (n = 791;27.1 %), HPV58 (n = 476;
16.3 %), HPV33 (n = 273; 9.4 %), HPV52 (n = 244; 8.4 %),
HPV18 (n = 201; 6.9 %), HPV56 (n = 191; 6.6 %), HPV66
(n = 134; 4.6 %), HPV31 (n = 123; 4.2 %), HPV59 (n = 93;
3.2 %), HPV68 (n = 78; 2.7 %), HPV51 (n = 72; 2.5 %),
HPV35 (n = 63, 2.2 %), HPV53 (n = 58; 2.0 %), HPV45
(n = 34; 1.2 %), HPV73 (n = 29; 1.0 %), HPV39 (n = 30;
1.0 %), HPV83 (n = 20; 0.7 %), and MM4 (n = 5;0.2 %).
Low-risk genotypes included HPV6 (n = 703; 40.8 %),
HPV11 (n = 505; 29.3 %), HPV43 (n = 403; 23.4 %),
HPV42 (n = 112; 6.5 %), and HPV44 (n = 1; 0.1 %) [7].
Furthermore, the detection rates of HPV-16 and 18 had
decreased and that of HPV-58 and HPV-33 had in-
creased over a 6-year period [7]. In addition to the ana-
lysis of the treatment and prevention in China, we also
obtained data related to the DNA of HPV-33 and HPV-58.
Chen et al showed that HPV-33 manifested two viral
lineages (A and B). The HPV-58 was classified into four
variant lineages (A, B, C and D) [27]. In the 124 HPV-
33 L1, our study samples matched with clade A, 111
samples in A1, and 13 samples in A2. All the 101 HPV-
33 L2 study samples matched clade A, 88 samples in A1,
and 13 samples in A2. All the 223 HPV-58 L1 study
samples matched clade A, 135 samples in A1, 65 samples
in A2, and 23 samples in A3. In case of 201 HPV-58 L2,
all our study samples matched clade A, 114 samples in
A1, 62 samples in A2, and 25 samples in A3. The se-
quence patterns of HPV-33 L1 and L2 were 13 and 8, and
for HPV-58, they were 37 and 24, respectively.
We demonstrated that HPV-58 L1 and L2 variation
frequencies were higher than those of HPV-33 L1 and
L2. Among these variations, C5807A, A5822G, G5984A,
A6437G, T6470C, T6485C and A6695C (E377D, which
is a positive selection variation) represented novel HPV-
58 L1 mutations, which were found until now only in
Sichuan, China [15, 17, 28–32]. In HPV-58 L2, muta-
tions other than A4621C and A5206G, were newly
reported [15]. In HPV-33 L1, T5960C, A5997G (K135R),
T6385G, G6396A (G268E), T6463C, G6520A, T6613C,
A6694G, A6951C (K453T), C7044A (P484H) and
G7063A were reported for the first time, these newly
reported mutations were only found in China in reports
related to HPV-33 L1 [30, 33, 34]. We reported the
HPV-33 L2 mutations for the first time.
The most common non-synonymous mutations of
HPV-33 L1 included T266K (18/124), T56N (13/124),
G133S (13/124) and E385D (13/124). The most common
non-synonymous mutations of HPV-33 L2 were D77N
(15/101), F281Y (8/101), D350H (6/101), D360N (6/
101), and N372T (6/101). The most common non-
synonymous mutations of HPV-58 L1 comprised L150F
(88/223), I135M (88/223), and T375N (62/223). The
most common non-synonymous mutations of HPV-58
L2 were A416T (146/201), N231T (24/201), and M446L
(24/201). Results of the selective pressure analysis sug-
gest that most positive selection mutations of HPV-33
and HPV-58 L1/L2 were common non-synonymous mu-
tations, indicating that the positive selection variations
beneficial for HPV-33 and HPV-58 adapted to their en-
vironments widely. The other variations in the positive
selection mutations were uncommon. However, with the
inheritance of the virus, positive variations may become
increasingly common and gain importance in the future.
The most common synonymous mutations of HPV-33
L1 were A6664G (18/124), T6613C (14/124), T6478C
(13/124) and A6673G (13/124). The most common syn-
onymous mutations of the HPV-33 L2 included C5220T
(101/101) and C4905T (9/101). The most common syn-
onymous mutations of HPV-58 L1 were A6416G (65/
223), T6434C (65/223), G6641A (65/223), and A6560G
(64/223); and those of the HPV-58 L2 were T4627C
(148/201), G5395C (146/201), and G5266A (86/201).
Due to the high diagnostic value of L1, and its variability
[35], L1 is often selected as a clinical diagnostic target.
We considered the most sites in common mutations to
design clinical diagnostic probes targeting HPV L1 and
Table 7 Site-specific tests for positive selection on HPV-33 L2
Models InL Estimates of parameters 2Δl Positively selected sites
M7 −2185.718 p = 0.005 q = 0.020 NA
M8 −2174.779 p0 = 0.985 p = 0.551 q = 5.040
(p1 = 0.015) ω = 20.381
21.878 p < 0.01 77D**, 350D**, 360D*, 372 N**
Table 8 Site-specific tests for positive selection on HPV-58 L1
Models InL Estimates of parameters 2Δl Positively selected sites
M7 −2849.987 p = 0.005 q = 0.048 NA
M8 −2821.953 p0 = 0.995 p = 0.006 q = 0.096 (p1 = 0.005) ω = 22.821 56.068 p < 0.01 150 L**, 318 F, 325I**, 375 T**, 377E
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L2 genes. The intratypic variations observed in L1 and
L2 enabled the analysis of known and novel HPV sub-
types [36, 37]. In our study, we observed that the
sequence patterns and single nucleotide changes of
HPV-33 L2 were less frequent than those of HPV-33 L1.
The sequence and single nucleotide changes of HPV-58
L2 were less frequent than those of HPV-58 L1, while
those of HPV-33 and HPV-58 L2 were more conserved
than those of L1, suggesting that HPV-33 and HPV-58
L2 were better candidates as clinical diagnostic targets
compared with HPV-33 and HPV-58 L1.
Nearly all conformational epitopes are located on one
or more of the outwardly facing surface-exposed loops
of BC, DE, EF, FG, and HI [38]. Sites 54, 55, 135–139,
141–143, 181, 182, 184, 267, 269, 270, 273, 278, 280,
282–287, 348, 354, 358, and 361 were previously
reported to be important for the Fab interaction [38].
Although we found no mutations at these Fab inter-
action sites, we did find several mutations (T56N,
K135R, T266K, and G268E of HPV-33 L1; N82T of
HPV-58 L1) next to these sites. We believe mutations
occurred on the outwardly facing surface-exposed loops
Table 9 Site-specific tests for positive selection on HPV-58 L2
Models InL Estimates of parameters 2Δl Positively selected sites
M7 −2432.604 p = 0.005 q = 0.048 NA
M8 −2424.886 p0 = 0.978 p = 2.63 q = 99.000
(p1 = 0.022) ω = 5.255
15.436 p < 0.01 231 N*,416A*,446 M*
Note: Tables 6, 7, 8 and 9: ln L, the log-likelihood difference between the two models; 2Δl, twice the log-likelihood difference between the two models; the
positively selected sites were identified with posterior probability ≥ 0.9 using Bayes empirical Bayes (BEB) approach ne asterisk indicates posterior probability≥ 0.95, and
two asterisks indicate posterior probability≥ 0.99. NA means not allowed. NS means the sites under positive selection but not reaching the significance level of 0.9
Fig. 3 Homology modeling of HPV-33 and HPV-58 variants. Note: Homology models based on the HPV-16 L1 pentamer crystal (PDB code: 2R5H).
a top and (b) side surface-filled views shown for HPV-33 and (c) top and (d) side surface-filled views shown for HPV-58 with external loops indicated
by dark grey shading. While all five monomers of the capsomer are pictured, adjacent external loops are indicated (purple, HI1; blue, BC1; red, DE2;
cyan FG2; green, EF2), and amino acid mutation is shown with black arrows and marked with yellow color in one of the five copies of a residue
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deserve research attention and should be studied for
vaccine design targeting HPV-33 and 58 L1.
Amino acid residues 69–81 and 108–120 of L2 protein
are highly conserved and contain cross-reacting epitopes
that play an important role in inducing neutralizing anti-
bodies [14]. G4438A (D77N) was discovered at residues
69–81 and 108–120 of HPV-33 L2. G4452A (G70E) and
G4470A (S76N) were identified at residues 69–81 and
108–120 of HPV-58 L2. Amino acid residues 33–52, 73–
84, 89–100, and 121–140 of L2 contain non-neutralizing
antibody epitopes [14]. G4438A (D77N) of HPV-33 L2
and The G4470A (S76N) of HPV-58 L2 were discovered
at residues 73–84. These mutations must be considered
during vaccine design targeting HPV-33 and 58 L2.
This is the first study examining the role of L1/L2 pro-
teins of HPV-58 variants in Sichuan and that of the L1/L2
proteins of HPV-33 in China. Because of limitations related
to sample size, sample copies, and sequencing technology,
the present study may have had a sampling bias against in-
tegrated HPV genomes. The data presented in this study
have significant implications for the understanding of in-
trinsic geographical and biological differences in HPV-33
and HPV-58 L1/L2, as well as contribute to the design of
clinical diagnostic probes and second-generation polyvalent
vaccine based on HPV-33 and HPV-58 L1/L2.
Conclusions
Mutations in HPV L1 and L2 may alter the virulence of
variants, and also define altered epitopes in vaccine design.
The reference sequences of HPV-33 and 58 only represent
minor sequence patterns of HPV-33 and 58 L1/L2. Fur-
ther, the distribution of HPV-33 and 58 L1/L2 variations
in Sichuan has its own peculiarities. Therefore, clinical
diagnostic probes and second-generation polyvalent vac-
cines should be designed on the basis of the unique se-
quence of HPV-33 and 58 L1/L2 variations in Sichuan,
whereby the accuracy of clinical detection and the protect-
ive efficiency of vaccines can be improved.
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Additional file 3: Figure S3. Sequence alignment of L1 from the HPV
types HPV16, HPV33, and HPV58. Note: The residues conserved across
four HPV types are shown in capital letters, whereas the nonconserved
residues are given in lowercase letters. The five loops displayed on the
surface of the virus particle are marked and labeled. (TIF 1448 kb)
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